Lifecore Biomedical Signs Commercial Transfer Agreement for Marketed Injectable Product
核心洞察
Lifecore Biomedical signed a new agreement to transfer a commercially marketed injectable drug product to its pipeline, supporting technical transfer and commercial manufacturing.
The agreement with a global pharmaceutical company marks Lifecore's seventh late-stage commercial program and eleventh program added to its pipeline in 2026.
The program is expected to generate commercial revenues in 2028 and is positioned to become one of Lifecore's largest contracts.
Lifecore Biomedical, Inc. (NASDAQ: LFCR), a fully integrated injectables contract development and manufacturing organization (CDMO), announced it has signed a new agreement to transfer a commercially marketed product to the company's pipeline. Under the terms of the agreement, Lifecore will perform technical transfer services to support commercial production of a strategically important injectable drug product with meaningful patient impact. The new agreement with a global pharmaceutical company marks Lifecore's seventh late-stage commercial program and the eleventh program added to its pipeline in 2026, with the program expected to generate commercial revenues in 2028.
"This product's unique formulation and manufacturing complexity align directly with Lifecore's strong technical expertise in high-viscosity, complex products," said Paul Josephs, chief executive officer of Lifecore. "Closing this opportunity reflects the solution-driven organization we're building - one positioned to deliver durable, sustained growth. We're proud to support this important therapy by applying our differentiated expertise to a technically complex manufacturing process."
Strategic Pipeline Expansion
The agreement underscores Lifecore's revamped commercial approach, which focuses on adding high-impact programs to its development pipeline. "A critical component of our growth strategy is our revamped commercial approach, focused on adding high-impact programs to our development pipeline," Josephs said. "The addition of this new program provides clear evidence that this strategy is working."
With the addition of this program, Lifecore's late-stage pipeline now contains thirteen programs that have the potential to generate commercial revenues by the end of 2028. The company emphasized that it is not only accelerating pipeline growth but also expanding its customer base, including the establishment of another high-potential relationship with a global pharmaceutical company.
Technical Expertise in Complex Injectables
The new program leverages Lifecore's differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market.
The company's technical strength in high-viscosity, complex products positions it to support the unique formulation and manufacturing complexity of the transferred product, reinforcing its role as a solution-driven CDMO partner for technically demanding injectable therapies.